| Drug General Information |
| Drug ID |
D08TGY
|
| Former ID |
DNC002585
|
| Drug Name |
S-(Dimethylarsenic)Cysteine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C5H12AsNO2S
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Toll-like receptor 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Human cytomegalovirus protease |
Target Info |
Inhibitor |
[1]
|
| Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Phagosome
|
|
PI3K-Akt signaling pathway
|
|
Toll-like receptor signaling pathway
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Proteoglycans in cancer
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritishsa00330:Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
TCR Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Toll receptor signaling pathwayP00005:Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Endogenous TLR signalinger_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
Reactome
|
Beta defensins
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Toll Like Receptor TLR6:TLR2 Cascade
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)R-HSA-1222556:ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
Toll-Like Receptors Cascades
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Defensins
|
|
Regulation of toll-like receptor signaling pathwayWP554:ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
Angiogenesis
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
